Kevin Chapla, MD
Pulmonary Disease · Austell, GANPI 1225398175
Payments from drug & device makers
Across 77 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$386
- AstraZeneca$299
- Boehringer Ingelheim$191
- Electromed, Inc.$178
- Insmed, Inc.$177
- La Jolla Pharmaceutical Company$163
- plus $615 from 16 others
What the payments were for
- Food & beverage$2,009100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $386 |
| AstraZeneca | 5 | $299 |
| Boehringer Ingelheim | 7 | $191 |
| Electromed, Inc. | 12 | $178 |
| Insmed, Inc. | 3 | $177 |
| La Jolla Pharmaceutical Company | 4 | $163 |
| Johnson & Johnson | 1 | $125 |
| Grifols USA, LLC | 4 | $81 |
| Mallinckrodt Enterprises LLC | 3 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Merck | 2 | $28 |
| Seagen Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Sanofi | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,009 in reported general payments places this provider in the 30th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Austell
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Sriram ParameshAustell$36K
- Steven HarrisAustell$35K
- Maria MascoloRincon$2.7M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.